As shown by AstraZeneca in Nature reviews*, one third of the safety failures is linked to CNS toxicity during the clinical trials of drugs. Therefore, relevant in vitro human models are needed to detect early neurotoxicity of drug candidates. In this study, sensitivity of iPSC-derived neuronal cells to 32 compounds was compared to the sensitivity of differentiated SH-SY5Y cells. Two types of iPSC-derived cells were tested: central nervous system cells (CNS.4U® cells) and peripheral nervous system cells (PERI.4U® cells) from Ncardia. Toxic effects were then measured using HCS cell imaging.

View and download on Slideshare (low quality) : https://www.slideshare.net/hcspharma/neurotoxicity-assessment-comparison-between-shsy5y-and-ipscderived-cells

Ask for high quality link by entering your email below

 

 

 

 


Grégory MAUBON

Grégory MAUBON is Chief Data Officer and digital coordinator at HCS Pharma, a biotech startup focused in high content screening and complex diseases. He manages IT missions and leads digital usages linked to company needs. He is also a Augmented Reality Evangelist (presenter and lecturer) since 2008, where he created www.augmented-reality.fr and founded in 2010 RA'pro (the augmented reality promotion association). He helped many companies (in several domains) to define precisely their augmented reality needs and supported them in the implementation.

1 Comment

Our last experience in ELRIG Fr and EUROoC meetings! | HCS Pharma · June 12, 2018 at 2:01 pm

[…] We presented two posters there, one about BIOMIMESYS hydroscaffold and the other about neurotoxicity testing. […]

Leave a Reply